Dilaram Khan, Fakhre Alam, Mohammad Iltaf, Muhammad Kamran Hassan, Hashmatullah Khan, Amir Ghafoor.
Effectiveness and safety of sofosbuvir and daclatasvir combination for the treatment of hepatitis C.
J Postgrad Med Inst Jan ;33(1):19-22.

Objective: To determine the effectiveness and safety of sofosbuvir and daclatsvir combination for the treatment of hepatitis C. Methodology: This study, of 145 patients, was done in the OPDs of Gastroenterology Unit, LRH & HMC of Khyber Pakhtunkhwa, from January 1 st 2017 to December 1 st , 2017. HCV infected Patients aged more than 18 years, of either gender, irrespective of previous treatment status having normal hematological tests and ultrasound were included. Results: Ninty three patients (64.13%) were male and 52 (35.86%) female. Mean age was 39.27 +-10.95. Genotype 3 was the most common genotype, present in 130 (89.65%) patients. All patients with HCV Genotype 3, Genotype 2 and Genotype 1 and untypeable had undetectable HCV RNA at week 4, while 122 (93.84%) patients with HCV Genotype 3; 6(85.71%) patients with Genotype 2; and 4(100%) each with Genotype 1 and untypeable had undetectable HCV RNA twelve weeks after treatment completion. Ten (6.89%) patients developed fatigue, 9(6.20%) patients developed nausea while 8(5.51) patients complained of headache. Conclusion: Combination of sofosbuvir and daclatasvir was found highly effective with high safety profile in HCV infected patients in our set up.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com